stockrowCeriBell, Inc.
CBLL Healthcare Medical Devices
CeriBell, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $89.1 million, up 36.1% from fiscal 2024.
- Revenue
- +29.9%
- EPS
- −49.9%
- Free cash flow
- −19.7%
- Total debt
- +1.29%
Quarter to September 2026, against a year earlier
Follow CBLL
Alert me
CeriBell, Inc. (CBLL) EV/Sales
As of 6 November 2026, CeriBell, Inc. (CBLL) trades at a EV/Sales of 8.5×. Over the past ten years it has ranged from 0.8× (January 2025) to 9.1× (November 2026); the current reading is higher than 98% of that period. That is above the Medical Devices industry median of 2.7× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.4× | 261.74% |
| FY2024 | 2.1× | (17.79%) |
| FY2023 | 2.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 7.7× | 25.19% |
| Jun 2026 | 6.2× | 3.28% |
| Mar 2026 | 6.0× | (19.45%) |
| Dec 2025 | 7.4× | 124.52% |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AHCO AdaptHealth Corp. compare | 0.8× |
| QDEL QuidelOrtho Corporation compare | 1.4× |
| BVS Bioventus Inc. compare | 1.6× |
| IART Integra LifeSciences Holdings Corporation compare | 1.6× |
| PRCT PROCEPT BioRobotics Corporation compare | 2.8× |
| BBNX Beta Bionics, Inc. compare | 3.8× |
| SIBN SiBone compare | 4.4× |
| CBLL CeriBell, Inc. | 8.3× |
| IRMD iRadimed Corporation compare | 11.4× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)